Rhizen Pharmaceuticals S.A. Announces a Scientific Presentation on the PI3K-Delta Inhibitor, TGR-1202, at the XV International Workshop on Chronic Lymphocytic Leukemia at Cologne, Germany

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

La Chaux-de-Fonds, Switzerland, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals announces a scientific poster presentation on the PI3K-delta inhibitor, TGR-1202, by the Duke University Medical Center, on 9th September 2013, at the IWCLL workshop in Cologne, Germany.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC